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INTRODUCTION 
Depression raises significant public health 
concerns. According to the National Comor-
bidity Survey Replication Study, the lifetime 
prevalence of major depressive disorder 
(MDD) in the U.S. population is 16.6% [1]. 
While not included in the MDD’s diagnostic 
criteria, anxiety is among the three most 
frequent signs (along with the symptoms of 
personality disorders and substance abuse) 
presented by depressive patients [2]. 
Although easy to overlook in general 
medical settings, depression and anxiety 
impose a significant burden on patients 
with various somatic diseases, and car-
diac patients are no exception to the rule. 
Epidemiological data suggests that MDD 
affects approximately 17–20% of those with 
coronary heart disease (CHD), 16–28% of 
myocardial infarction (MI) survivors [3] (with 
even higher ratios of subclinical depressive 
syndromes [4]), and 30% of patients with 
heart failure (HF) [5]. 
The negative impact of MDD on the 
risk of developing CHD and on the disease’s 
subsequent course has become widely 
acknowledged. It has also been confirmed 
that depression is a major contributor to 
increased mortality, morbidity, rehospitalisation rates, reduced 
health status and functional impairment in patients with con-
gestive heart failure (CHF) [6]. Notably, MDD has been found 
to be independent risk factor for early-onset cardiovascular 
diseases (CVD) and CHD-related mortality in a sample of 
patients below 40 years of age [7]. 
The following four pathophysiological mechanisms have 
been posited to account for the link between CVD and MDD: 
alterations in platelet activity, increased activity of inflam-
matory cytokines, decreased heart rate variability (HRV), 
and hyperactivity of the hypothalamic-pituitary-adrenal axis 
(implying activation of the sympathetic nervous system) [8]. 
It should not be forgotten that the CVD-MDD relation-
ship is a mutual one. While discussing the common ground 
between depression and HF, Nair et al. [9] noticed that de-
pressed patients are less active, often cling to an inadequate 
diet, have worse compliance with medication, and are more 
prone to abusing tobacco and alcohol. Thus, such beha-
vioural disturbances may exert deleterious effects on both the 
course of HF and the patient’s self-image, possibly leading to 
the exacerbation of depression. Also, as heavy smoking has 
been found to be an independent risk factor for MDD [10], 
it is worth mentioning that nicotine dependence seems to be 
a pathogenetic common ground for both depression and CVD. 
Given these facts, the aim of this review was to highlight 
the importance of the accurate diagnosis and treatment of anxi-
ety and depression in patients attending cardiologic facilities. 
ANXIETY AND DEPRESSION  
IN GENERAL MEDICAL SETTINGS
Two major symptomatic manifestations of anxiety would seem 
to be of special importance in the realm of somatic medicine: 
somatoform disorders (somatisation, hypochondria and auto-
nomic dysfunctions observed in the absence of any somatic ill-
ness), and somatic anxiety secondary to a medical condition [6]. 
The most common non-somatic symptom that patients 
report to physicians is panic anxiety (the basic sign of panic 
disorder). Panic anxiety is described as an acute episode of 
anxiety accompanied by feelings of impending doom (immi-
nent myocardial infarction, asthma exacerbation or death). 
While panic disorder frequently co-occurs with asthma 
(especially with the severe and aspirin-induced types of the 
disease) [11], it is worth mentioning that high-trait anxiety 
is also a common feature of patients with co-morbid heart 
disease and anxiety disorder — particularly in the course of 
CHD exacerbation [6]. 
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Depression is a serious problem in a variety of medical 
illnesses. For example, approximately 40% of subjects with 
diabetes experience depressed mood and 25% have clinically 
significant depression that requires pharmacotherapy. The 
relationship between mental disorders and diabetes appears 
mutual, as the risk of developing diabetes is 37% higher in 
a group of patients with psychiatric disorders (compared to 
the general population) [12]. Among subjects with cancer, the 
prevalence of depression is estimated to be as high as 8–57% 
(the exact figure depends on the type and stage of the disease) 
[13]. Patients with renal failure or liver insufficiency often ex-
perience anxiety and depressive disorders, as well as dementia 
or psychosis [14]. Finally, it is worth mentioning that subjects 
with autoimmune diseases are also prone to developing vari-
ous neuropsychiatric syndromes, including anxiety, depression, 
cognitive disorders, memory impairment and psychosis [15]. 
DEPRESSION AND ANXIETY IN PATIENTS  
TREATED FOR CARDIOLOGIC DISEASES 
The question of the relationship between depression and 
anxiety and CVD is a multi-dimensional one. On the one 
hand, the findings indicating that depression and CVD share 
pathophysiological determinants are known, while on the 
other hand MDD is an independent factor that influences 
the course of numerous CVD [16]. Furthermore, the applica-
tion of some methods of treatment for patients with CVD has 
a significant influence on the risk of anxiety or depression. 
Anxiety in patients with cardiovascular diseases 
Though anxiety is probably the most frequent psychopatho-
logical symptom in patients who have suffered acute cardio-
vascular episodes (this is experienced by 70–80% of patients 
in this group), it is also a serious problem in those who have 
chronic forms of CVD. It is estimated that 20–25% of patients 
in the latter population experience long-term, persistent anxie-
ty. Among those with HF, anxiety is even more frequent (it is 
experienced by 25–50% of patients in this group) [17]. The 
presence of this symptom impedes patients in their adapta-
tion to the difficult situation produced by the chronic illness 
and is associated with lower quality of life, greater difficulty 
in absorbing and acting on medical recommendations, and 
slower recovery following acute CVD episodes. The anxiety 
experienced by patients with CVD is a predictor for greater 
severity of the symptoms of the underlying disease and, as 
a consequence, a greater level of functional impairment. In 
assessing the level of anxiety in patients with somatic diseases, 
particular attention should be paid to the accounts of the 
patients themselves, as the objective symptoms regarded as 
‘markers’ of anxiety, such as heart rate or blood pressure, 
are not reliable in patients with acute episodes of CVD [18]. 
De Jong et al. [19] demonstrated that the level of anxiety 
experienced by those with recent MI is on average 44% greater 
than in a healthy population. At the same time, the level of 
anxiety in women was approximately 25% greater than in 
men. This finding supplies a further argument in favour of the 
need for anxiolytic therapy for the patients in this group, as 
anxiety is a risk factor in the occurrence of MI complications 
(arrhythmias or further episodes of MI) and is also associated 
with greater mortality. Moreover, the value of this risk is in direct 
proportion to the severity of the anxiety. The pathogenic basis 
for the relationship between anxiety and a poor prognosis in 
MI is not known. Moser [18] suggests that the physiological (for 
example, activation of the sympathetic nervous system) and be-
havioural (for instance, poorer co-operation during treatment) 
correlates of anxiety could be connected with unsatisfactory 
therapy results. She also points out that this problem appears 
to be specific to MI, as the data on the influence of anxiety 
on the prognosis in other CVDs is ambiguous. 
Influence of depression on the course  
of cardiovascular diseases
The characteristic feature of MDD in patients with cardiologic 
diseases is the long-term persistence of its symptoms. Based 
on a review of the literature, Celano and Huffman [16] found 
that 50–70% of patients hospitalised because of acute cardio-
vascular episodes already met the diagnostic criteria for MDD 
before the episode, while in patients with stable CHD the 
symptoms of depression often precede acute decompensated 
HF by many months (or even years). 
The co-occurrence of MDD and CVD significantly af-
fects the results of treatment. It has been shown that patients 
with CHD and depression who have had coronary artery 
bypass graft (CABG) operations achieved poorer functional 
outcomes, experienced lower quality of life, had faster deve-
loping atherosclerosis, and greater rates of re-hospitalisation 
and mortality [16]. 
Ample data has been compiled suggesting that the risk 
of occurrence of further episodes of acute CHD is greater 
in patients whose depression developed after MI than in 
patients without depression [16]. However, the conclusion 
that depression has a negative influence on the prognosis of 
patients after MI does not appear surprising: it is now known 
that not every subtype of MDD is associated with a greater 
risk of complications in this group of patients. Martens et al. 
[20] found that — following MI — patients who suffered from 
depression with somatic/affective symptoms were characte-
rised by reduced left ventricular ejection fraction, experienced 
further episodes of MI more often and were at greater risk of 
death. The occurrence of MDD as manifested by the pres-
ence of cognitive/affective symptoms was not associated with 
these effects. De Jonge et al. [21] discovered that patients 
suffering from MDD with somatic symptoms had lower HRV, 
which could lead to worse outcomes in some cases of CVD, 
including MI. Other factors that could play a significant role 
in the pathogenesis of ‘post heart attack’ depression include 
the increased activity of pro-inflammatory cytokines accompa-
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nying left ventricular dysfunction, and functional impairment 
resulting from MI [22]. 
When considering the relationship between poorer 
prognosis and the clinical signs of depression, it is worth re-
membering that this is not only found with MI but also with 
other CVDs. According to Celano and Huffman [16], the fol-
lowing psychiatric factors of prognosis are especially adverse 
in patients suffering from these illnesses: treatment-resistant 
depression, depression accompanied by anxiety, depression 
with significant anhedonia and the depression that accom-
panies type D personality traits (expressed by negative affect 
and social inhibition). 
Some researchers have pointed to the existence of 
‘arrhythmogenic properties of depression’. This conclusion 
was drawn based on evidence that individuals with MDD 
who have experienced MI have a higher risk of death due to 
ventricular arrhythmias. It is also known that in patients with 
atrial fibrillation (AF) who have undergone cardioversion, 
the risk of recurrence of this illness is greater in the case of 
co-occurrence with MDD [16]. 
It would appear, moreover, that depression is an adverse 
prognostic factor in some populations of patients with ar-
rhythmias. Frasure-Smith et al. [23] demonstrated that patients 
with HF and AF who experienced mild or significant MDD 
were at greater risk of death from cardiovascular causes than 
patients without depression. 
The co-occurrence of depression leads to significantly 
worse treatment results for patients with HF. The results of 
a meta-analysis conducted by Rutledge et al. [24] suggest that 
the combined risk of repeated cardiovascular episodes, or of 
death, in patients with MDD and HF is approximately twice 
as great as in patients who have HF but are unaffected by de-
pression. These patients are also hospitalised more often and 
make more visits to hospital accident and emergency depart-
ments. Jiang et al. [25] found that the severity of symptoms of 
depression was a differentiating factor in the risk of death in 
patients with HF. Jiang’s team observed that patients whose 
severity of depression corresponded with a score of  ≥ 19 on 
the Beck Depression Inventory (BDI) were subjected to a risk 
of death as much as 83% greater compared to patients who 
had scores of < 5 on the same scale. It is significant that MDD 
is not only one of the possible outcomes of HF, but can also 
be a factor that leads to this illness. The authors gathered their 
evidence for this thesis by studying patients with CHF. As the 
studies proceeded, it was observed that depression acts in syn-
ergy with other risk factors for the development of CHF [16]. 
Influence of specific therapeutic methods  
employed in patients with cardiovascular diseases 
on the risk of depression or anxiety
Numerous studies have been devoted to the occurrence of 
depression in individuals being treated for CVDs (both con-
servatively and with the use of invasive methods). 
Probably the largest number of studies analysing the 
relationship between the use of ‘cardiologic’ medicines and 
the risk of the development of depression concern beta-block-
ers. Despite the widespread opinion that these medicines have 
depressionogenic potential, it would appear that the greater 
risk of occurrence of MDD is mainly associated with patients 
who take the most lipophilic (i.e. most easily breaching the 
blood-brain barrier) of beta-blockers: propranolol. The data 
that is currently available does not confirm that there exists 
a ‘depressionogenic group effect’ of beta-blockers. However, 
because the use of lipophilic beta-blockers in individuals with 
a family history of MDD can increase the risk of occurrence 
of depression, it is necessary to pay particular attention to 
changes in mental state in this group of patients with CVD. Yet, 
taking into account that the use of these medicines significantly 
reduces morbidity and mortality in patients with CVD, the re-
sults of using beta-blockers — even in individuals from groups 
at risk of MDD — would appear beneficial [26]. It is worth 
remembering that taking such medicines as interferon alpha 
(whose use is associated with a risk of occurrence of MDD 
of 20–40% [27]), angiotensin-converting enzyme inhibitors, 
thiazide diuretics, calcium channel blockers, corticosteroids, 
anticonvulsants and certain nonsteroidal anti-inflammatory 
drugs (especially indometacin) may also lead to the occur-
rence of symptoms of depression [28]. 
The occurrence of the symptoms of depression or 
anxiety is a significant problem in individuals with HF who 
have received implantable cardioverter-defibrillators (ICD). 
Freedenberg et al. [29] noted that though employing ICDs 
undoubtedly contributed to the reduction of morbidity in 
patients with HF, their mental state often left much to be de-
sired, as the symptoms of depression were present in 24–33% 
of them and anxiety was experienced by 24–87% of patients 
with HF and ICDs. 
The most important risk factors for the occurrence of 
these symptoms are being young, being female and frequent 
ICD discharges [30]. 
The authors cited above emphasise that one of the 
conditions for the proper care of patients with ICDs is the 
prevention of the occurrence of anxiety and depression. It 
is necessary to work towards the maximum stabilisation of 
the clinical states of these patients and — as a consequence 
— limit the number of ICD discharges. Screening for anxiety 
or depression in patients who are to undergo ICD therapy can 
make it possible to identify those who require psychological 
or psychiatric care. Where patients who already have ICDs 
are concerned, it is necessary to assess the severity of the 
symptoms of depression and anxiety every six months [29]. 
Anxiety very frequently accompanies patients who are 
receiving revascularisation procedures. According to Trotter et 
al. [31], this symptom is experienced by 24–72% of individuals 
who undergo percutaneous coronary intervention (PCI). Trot-
ter’s team noted, however, that the level of anxiety before PCI 
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is usually not very high and that it decreases continuously over 
time following the procedure. Those who experience chest 
pain after the procedure, and those who have undergone 
PCI for the first time, are at risk of particularly severe anxiety. 
Taking anxiolytics or antidepressants is a further risk factor for 
the occurrence of symptoms of anxiety before PCI. 
In research that included patients who had undergone 
CABG, Pawlak et al. [32] found a negative correlation between 
age and the intensity of anxiety experienced following the 
procedure, and a positive correlation between the severity of 
the anxiety and the level of symptoms of depression. Pawlak’s 
team also found that the anxiety experienced by women fol-
lowing CABG is more intense than that of men. 
Finally, it is worth mentioning that depression is one of 
the common complications of cardiac surgery [33]. Freedland 
et al. [34] reported that full-blown MDD episodes develop in 
approximately 20% of individuals who undergo CABG proce-
dures. Patients who experience perioperative depression more 
frequently experience surgical complications, require more 
time for full convalescence and have a poorer quality of life. 
Moreover, the subjective sense of the presence of cognitive 
dysfunction is more intense in them than in more tranquil 
individuals, and they are also at greater risk of cardiovascular 
episodes or death. 
DIAGNOSTIC DIFFICULTIES
Even though MDD occurs very often in individuals with 
cardiologic diseases, it often escapes the attention of doctors 
[16]. There is data suggesting that depression is diagnosed in 
only 25% of patients with co-occurring CHD and MDD, while 
only 12.5% of these patients receive adequate antidepressive 
therapy [3]. The non-specificity of the depressive symptoma-
tology observed in this population of patients (who often 
suffer from a sense of fatigue, a loss of appetite, weakened 
libido, and a general feeling of poor health and spirit) and the 
domination of somatic symptoms (often the result of what 
is known as catastrophic interpretation of body sensations 
— characteristic for MDD, as well as for panic disorder [35]), 
mean depressive symptoms of negligible or mild intensity are 
often interpreted as signs of poor general medical condition, or 
as adverse effects of the medicines being used. Furthermore, 
patients often do not report symptoms of depression in the 
belief that doctors are interested only in somatic symptoms [6]. 
Assessment of the mental state of the patient should be 
a permanent feature of clinical examination — including 
for doctors who are not psychiatrists [6]. This principle was 
adopted in the guidelines produced by experts at the Ameri-
can Heart Association (AHA), who stated that screening for 
depression is necessary for all patients with CHD [36]. 
When examining patients with suspected depressive 
disorders, particular attention should be paid to the presence 
of depressive cognitive styles (arranged in the Beck triad of 
pessimistic thoughts about oneself, the world and the future), 
as well as to suicidal ideations and statements from patients 
referring to low quality of life and sense of guilt [6, 37]. These 
symptoms often obscure the negative symptoms of depres-
sion, which are depressed mood, anhedonia (reduction or 
complete loss of the capacity to experience pleasure), and 
increased fatigue or loss of energy [38]. Because distinguishing 
between MDD and the ‘poor spirit’ experienced by individu-
als with serious somatic diseases can be difficult, it is worth 
remembering that the major symptom of depression in indi-
viduals with general medical conditions is often anhedonia, 
while those who are demoralised usually speak of feelings of 
helplessness and disempowerment [28]. 
According to the AHA experts [36], the basic tool facilitat-
ing the identification of MDD in individuals with cardiologic 
diseases is the Patient Health Questionnaire-9 (PHQ-9) [39]. 
There are also other scales that can be used, such as the 
Hospital Anxiety Depression Scale (HADS) [40], the Geriatric 
Depression Scale (GDS) [41] and the ‘classic’ depression-diag-
nosis tools: BDI, the Montgomery-Asberg Depression Rating 
Scale (MADRS) and the Hamilton Rating Scale for Depression 
(HDRS) [42]. Conducting neuropsychological diagnostics (in 
co-operation with a clinical psychologist) in individuals who 
have had cardiac surgery may help in differentiating the de-
pressive feeling of cognitive impairment from ‘real’ cognitive 
disorders [43, 44]. 
In discussing the various tools used in the diagnosis of 
depression, it is necessary to remember that the ‘tool’ with 
perhaps the greatest sensitivity and specificity with respect to 
depressive disorders in individuals with chronic diseases is the 
question: ‘Are you depressed?’ [28, 45]. This seemingly trivial 
observation is all the more important in that the results of all 
the systematic reviews with meta-analyses have suggested 
that some of the universally applied tests designed to facilitate 
diagnosis of MDD in patients with CVD (BDI, HDRS, HADS) 
have unsatisfactory psychometric properties [46, 47]. 
TREATMENT OF ISCHAEMIC HEART DISEASE 
AND DEPRESSION 
The small quantity of data originating from randomised 
controlled trials and the necessity for further research into 
the cause and effect relationship between CHD and MDD 
explain why an algorithm for the therapy of patients suffering 
from these disorders has not yet been developed. The present 
guidelines are composed mainly of expert opinions, which 
means that their reliability is limited [48]. 
Based on the results of literature reviews, Ramasubbu et 
al. [49] and Mavrides and Nemeroff [8] have suggested that in 
the process of treating patients with depression and CHD, it is 
necessary to employ both pharmacological and psychosocial 
interventions. The results of most randomised controlled trials 
(SADHART, CREATE, ENRICHD, MIND-IT) have indicated that 
selective serotonin reuptake inhibitors (SSRI) are the safest 
therapeutic option for patients in the group under discussion. 
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They produce few adverse effects and, compared to a placebo, 
effectively reduce the severity of depressive symptoms (though 
it is worth mentioning that the results of the SADHART-CHF 
randomised controlled trials lead to less optimistic conclu-
sions regarding the effectiveness of SSRI). Because most of 
the promising scientific data on the effectiveness and safety of 
employing antidepressants in individuals with CHD and MDD 
concerns sertraline, Mavrides and Nemeroff [8] deemed it to be 
the first-choice antidepressant for these patients. Other SSRIs, 
such as fluoxetine, paroxetine, citalopram and escitalopram, 
would appear equally effective. However, before making the 
decision to use one of them, it is necessary to conduct a risk 
analysis for the occurrence of drug interactions (the risk is 
particularly great in the case of fluoxetine used together with 
propranolol or metoprolol, paroxetine or fluvoxamine used 
with IC class antiarrhythmic medicines or theophylline, and 
also citalopram with digitalis) [8, 50]. 
It is important to remember that combined use of anti-
depressants and antipsychotics is a significant risk factor of 
sudden cardiac death in patients undergoing acute coronary 
events [51]. 
When using tricyclic antidepressants (amitriptyline, 
doxepin or clomipramine) it is important to be aware of the 
risk of orthostatic hypotension — especially in patients with 
left-ventricular impairment [50]. While there is a lack of data 
on the effectiveness and safety of the long-term use of tricy-
clic antidepressants (TCA) in patients with CHD and MDD, it 
is necessary to remember their pharmacodynamics renders 
them similar to class I antiarrhythmic drugs according to the 
Vaughan Williams classification. Acting as inhibitors of the 
sodium channels and also as inhibitors of the fast potassium 
channels, they can prolong the QT interval, whose effect in 
turn can be potentially lethal arrhythmias (for example, torsade 
de pointes or ventricular fibrillation) [8]. In this way, danger-
ous interactions of TCAs with antiarrhythmic medicines can 
occur. Although it would appear that TCAs can be safely used 
in patients with mild intra-ventricular conduction abnormali-
ties, they are contra-indicated for patients with atrioventricular 
block, right bundle branch block, cardiac arrhythmia, and in 
the period directly following an MI [50]. 
Data on the subject of the effectiveness and safety of 
using other antidepressants in patients with CHD and MDD 
is a great deal more scarce, yet it would seem that in this 
group of patients bupropion could be used with satisfactory 
outcomes. Although the authors of the MIND-IT research did 
not find that mirtazapine had an advantage over a placebo 
in terms of reducing the severity of depressive symptoms in 
patients in the post heart attack period, they did discover 
that individuals who had not had any therapeutic response 
from using antidepressants were at a significantly greater risk 
of a further cardiovascular episode [8]. 
Of the non-pharmacological interventions that can be 
employed in individuals with CHD and MDD, the implemen-
tation of cognitive-behavioural therapy (CBT), interpersonal 
therapy or problem-solving therapy is recommended [49].
Some data suggests that the application of CBT leads 
to a reduction in mortality in patients with CHD and MDD 
[8]. The results of observational studies suggest that exercise 
training can limit the severity of depressive symptoms [52]. It 
would thus appear that patients participating in cardiologic 
rehabilitation programmes have the opportunity to benefit 
not only from improvements in the functioning of their car-
diovascular systems, but also from reductions in the suffering 
caused by depression. 
SUMMARY
The co-occurrence of depression and CVD is a serious but 
underestimated clinical problem. The presence of depressive 
disorders exerts a negative influence on the results of treat-
ment of patients with CVD. 
It is necessary to conduct screening for depression in all 
patients with cardiac diseases, while the appropriate phar-
macological and psychosocial therapies should be applied in 
patients confirmed as having depressive disorders. 
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